Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Real-World Tumor Response of Palbociclib plus Letrozole versus Letrozole for Metastatic Breast Cancer in US Clinical Practice

2021 Year in Review - Breast Cancer - Breast Cancer

The objective of this study was to compare the real-world tumor response of palbociclib plus the aromatase inhibitor letrozole versus letrozole alone in patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer in the United States.1

Using the Flatiron Health Analytics database, procedures and patients with HR-positive, HER2-negative metastatic breast cancer who received palbociclib plus letrozole or letrozole monotherapy as first-line treatment between February 2015 and September 2018 were included in this retrospective research. Patients were followed up through December 2018. The best tumor response in the real world was calculated using physicians’ assessments of radiologic evidence for changes in disease burden.1

Approximately 70% of the 1383 eligible patients who received the palbociclib plus letrozole combination (N = 662) or letrozole monotherapy (N = 306) as first-line therapy had ≥1 tumor response evaluations. In the first-line scenario, the real-world best tumor response rate (full response plus partial response) was 59.8% in the palbociclib plus letrozole group and 39.2% in the letrozole monotherapy group (P <.0001). The real-world best tumor response rate in the palbociclib plus letrozole group was 58.6% versus 39.1% in the letrozole group after 1:1 propensity score matching.1

In this large cohort of general oncology practice patients in the United States, patients with HR-positive, HER2-negative metastatic breast cancer treated with first-line palbociclib plus letrozole had a considerably higher likelihood of tumor response than those treated with letrozole alone. Furthermore, when compared with letrozole alone, treatment with first-line palbociclib plus letrozole resulted in significant improvements in real-world progression-free survival and overall survival.1

These findings support palbociclib plus letrozole as a standard-of-care treatment for patients with HR-positive, HER2-negative metastatic breast cancer, and they add to the therapeutic benefit shown with palbociclib plus endocrine therapy in randomized clinical studies.1

Reference

  1. Brufsky A, Liu X, Li B, et al. Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. Target Oncol. 2021;16:601-611. Erratum in: Target Oncol. 2021;16:865.
Related Items
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report
Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Tumor Lysis Syndrome, Breast Cancer
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice
February 2022 Clinical Trials to Clinical Practice published on February 3, 2022 in Clinical Trials, Breast Cancer
2021 Breast Cancer Year in Review Introduction
2021 Year in Review - Breast Cancer published on January 21, 2022 in Breast Cancer
Copyright © The Lynx Group, LLC. All rights reserved.